Repeat-dose Study of Lenalidomide (Revlimid ®) Plus Dexamethasone in Patients With Lymphoblastic Leukemia (RV-405 LAL)

The recruitment status of this study is unknown because the information has not been verified recently.
Verified January 2011 by Institut de Cancérologie de la Loire.
Recruitment status was  Recruiting
Sponsor:
Collaborator:
Celgene Corporation
Information provided by:
Institut de Cancérologie de la Loire
ClinicalTrials.gov Identifier:
NCT01116193
First received: April 26, 2010
Last updated: January 14, 2011
Last verified: January 2011
  Purpose

The study objectives are to evaluate the safety and efficacy of the oral administration of lenalidomide in combination with dexamethasone in the treatment of adult patients with refractory or relapsed non-Ph+ B-cell lineage acute lymphoblastic leukemia (ALL).


Condition Intervention Phase
Leukemia, Lymphoid
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
Drug: Lenalidomide plus dexamethasone
Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase II, Multi-center, Open-label, Repeat-dose Study of Lenalidomide (Revlimid ®) Plus Low-dose Dexamethasone in Patients With Refractory B Cell Lineage Acute Lymphoblastic Leukemia or in Relapse After 2 Lines of Treatment

Resource links provided by NLM:


Further study details as provided by Institut de Cancérologie de la Loire:

Primary Outcome Measures:
  • Disease-Free survival (DFS) [ Time Frame: 2 years ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Time to response [ Time Frame: 28 days ] [ Designated as safety issue: No ]
  • Duration of response [ Time Frame: 2 years ] [ Designated as safety issue: No ]
  • To determine quality of life (QOL): European Organization for Research and Treatment of Cancer QOL questionnaire for patients with cancer (EORTC QLQ-C30) [ Time Frame: All 28 days ] [ Designated as safety issue: No ]
  • Progression-free survival [ Time Frame: 2 years ] [ Designated as safety issue: No ]
  • Feasibility of stem cell transplantation (SCT), in case of response, after one or more cycles of lenalidomide plus dexamethasone therapy [ Time Frame: all 28 days ] [ Designated as safety issue: No ]
  • Safety of lenalidomide plus dexamethasone: adverse events (type, frequency, severity of adverse events, and relationship of adverse events to study drug). [ Time Frame: All 28 days ] [ Designated as safety issue: Yes ]
  • To assess the efficacy of lenalidomide plus low-dose dexamethasone: complete response (CR), complete response without platelets (CRp), partial response (PR), and overall response (CR + CRp + PR). [ Time Frame: 1, 8, 15, and 22 of each 28-day cycle (4-weeks cycles) and after treatment, patients will be seen at least twice weekly until they attain a CR ] [ Designated as safety issue: No ]
  • Overall survival [ Time Frame: 2 years ] [ Designated as safety issue: No ]

Estimated Enrollment: 27
Study Start Date: January 2010
Estimated Study Completion Date: July 2013
Estimated Primary Completion Date: July 2011 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: Lenalidomide plus dexamethasone
    Lenalidomide 25 mg p.o. once daily on days 1-21 plus Dexamethasone 40 mg p.o. once daily on days 1, 8, 15, and 22 of each 28-day cycle (4-weeks cycles) until CR achievement, progression of disease or intolerable toxicity
    Other Name: Revlimid ®, 25mg
Detailed Description:

The study consists of two periods, an initial treatment period and an extended treatment period. Patients who meet all eligibility criteria will receive: Lenalidomide 25 mg p.o. once daily on days 1-21 plus Dexamethasone 40 mg p.o. once daily on days 1, 8, 15, and 22 of each 28-day cycle (4-weeks cycles) until CR achievement, progression of disease or intolerable toxicity. The daily dose of Lenalidomide and that of Dexamethasone will remain fixed. No dose adaptations are allowed according to the hematologic toxicity. However, in case of non-hematologic grade > 2 toxicity, the next cycle may be delayed up to 21 days after the onset of the event until the adverse event has returned to baseline or ≤ grade 1. Patients may be allowed to receive a pre-treatment with high doses of dexamethasone for initial hyperleukocytosis at the discretion of the investigator. The use of hematopoietic growth factor (HGF) during the initial or extended treatment period is also let at the discretion of the investigator. At the end of the initial treatment period, all responding patients (without HLA compatible donor) or patients showing sufficient clinical activity will be allowed to receive extended treatment with cycles identical to the first cycle. Patients may continue to receive treatment as long as the patient is tolerating the treatment well and the patient's physician believes the patient is receiving some benefit. The severity of adverse events will be graded according to the World Health Organization (WHO) criteria. Any life-threatening adverse effects that are observed during the initial or extended treatment period, which are possibly or probably related to study drug, will require the subject to discontinue study treatment.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Documented B-cell lineage acute lymphoblastic leukemia (non-Philadelphia positive chromosome), which under WHO guidelines is now referred to as precursor B-lymphoblastic leukemia/lymphoma.
  • Must have failed to at least two treatment regimens for B lineage ALL or must be refractory to chemotherapy. The inclusion of a patient with Ph+ ALL can be possible after contacting the principal investigator in presence of a T315I mutation and absence of investigational trial targeting this abnormality.
  • Performance status of ≤ 2 by Eastern Cooperative Oncology Group (ECOG) criteria.
  • Any age ≥ 18 years is allowed.
  • Life expectancy of at least 3 months.
  • Adequate liver function (aspartate transaminase [AST] and/or alanine transaminase [ALT] not > 3 times upper limits of normal).
  • Adequate kidney function (calculated creatinine clearance > 50 ml/min).
  • Signed informed consent prior to start of any study-specific procedures.
  • The patients refusing the preservation of their biological samples can however participate in the study.
  • All subjects must

    • Agree to abstain from donating blood while taking study drug therapy and for one week following discontinuation of study drug therapy.
    • Agree not to share study medication with another person and to return all unused study drug to the investigator

Female subjects of childbearing potential must :

  • Understand that the study medication is expected to have a teratogenic risk
  • Agree to use, and be able to comply with, effective contraception without interruption, 4 weeks before starting study drug, throughout the entire duration of study drug therapy (including dose interruptions) and for 4 weeks after the end of study drug therapy, even if she has amenorrhoea. This applies unless the subject commits to absolute and continued abstinence confirmed on a monthly basis. The following are effective methods of contraception

    • Implant
    • Levonorgestrel-releasing intrauterine system (IUS)
    • Medroxyprogesterone acetate depot
    • Tubal sterilization
    • Sexual intercourse with a vasectomised male partner only; vasectomy must be confirmed by two negative semen analyses
    • Ovulation inhibitory progesterone-only pills (i.e., desogestrel)
    • If not established on effective contraception, the female subject must be referred to an appropriately trained health care professional for contraceptive advice in order that contraception can be initiated
  • Understand that even if she has amenorrhea, she must follow all the advice on effective contraception.
  • Understand the potential consequences of pregnancy and the need to rapidly consult if there is a risk of pregnancy
  • Agree to have a medically supervised pregnancy test with a minimum sensitivity of 25 mIU/mL on the day of the study visit or in the 3 days prior to the study visit once the subject has been on effective contraception for at least 4 weeks. This requirement also applies to women of childbearing potential who practice complete and continued abstinence. The test should ensure the subject is not pregnant when she starts treatment
  • Agree to have a medically supervised pregnancy test every 4 weeks including 4 weeks after the end of study treatment, except in the case of confirmed tubal sterilization.

Criteria for women of non-childbearing potential

A female subject or a female partner of a male subject is considered to have childbearing potential unless she meets at least one of the following criteria:

  • Age ≥ 50 years and naturally amenorrhoeic for ≥ 1 year (Amenorrhoea following cancer therapy does not rule out childbearing potential.)
  • Premature ovarian failure confirmed by a specialist gynaecologist
  • Previous bilateral salpingo-oophorectomy, or hysterectomy
  • XY genotype, Turner syndrome, uterine agenesis.

Male subjects must

  • Agree to use condoms throughout study drug therapy, during any dose interruption and for one week after cessation of study therapy if their partner is of childbearing potential and has no contraception.
  • Agree not to donate semen during study drug therapy and for one week after end of study drug therapy.

Exclusion Criteria:

  • Active serious infection not controlled by oral or intravenous antibiotics.
  • Treatment with any investigational antileukemic agent or chemotherapy agent in at least 7 days prior to study entry and lack of full recovery from side effects due to prior therapy independent of when that therapy was given.
  • Rapidly progressive disease with compromised organ function judged to be life-threatening by the Investigator.
  • Patients with clinical evidence of active central nervous system (CNS) disease.
  • Pregnant and/or lactating female.
  • Patients with known human immunodeficiency virus (HIV) infection.
  • Patients with known active hepatitis B and/or hepatitis C infection.
  • Hypersensitive or intolerant to any component of the study drug formulation.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01116193

Contacts
Contact: Katy Couderc, CRA (33) 477127444

Locations
France
CHU de Clermont-Ferrand Recruiting
Clermont-Ferrand, France, 63003
Contact: Olivier Tournilhac, MD         
Principal Investigator: Olivier Tournilhac, MD         
Hôpital Michallon Recruiting
Grenoble, France, 38000
Contact: Jean-Yves Cahn, MD         
Principal Investigator: Jean-Yves Cahn, MD         
Hôpital Edouard Herriot Recruiting
Lyon, France, 69003
Contact: Xavier Thomas, MD         
Principal Investigator: Xavier Thomas, MD         
Institut de Cancerologie de la Loire Recruiting
St Priest en Jarez, France, 42271
Contact: Jérôme Cornillon, MD       jerome.cornillon@icloire.fr   
Sub-Investigator: Jérôme Cornillon, MD         
Sponsors and Collaborators
Institut de Cancérologie de la Loire
Celgene Corporation
Investigators
Principal Investigator: Emmanuelle Tavernier, MD Institut de Cancérologie de la Loire
  More Information

No publications provided

Responsible Party: Dr. Emmanuelle Tavernier, Institut de Cancérologie de la Loire
ClinicalTrials.gov Identifier: NCT01116193     History of Changes
Other Study ID Numbers: 2009-01b, 2009-009372-13
Study First Received: April 26, 2010
Last Updated: January 14, 2011
Health Authority: France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)

Keywords provided by Institut de Cancérologie de la Loire:
antileukemic therapy
lymphoblastic leukemia
lenalidomide
dexamethasone

Additional relevant MeSH terms:
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Leukemia, Lymphoid
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
Leukemia
Neoplasms by Histologic Type
Neoplasms
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Dexamethasone acetate
Dexamethasone
Dexamethasone 21-phosphate
Lenalidomide
Thalidomide
BB 1101
Anti-Inflammatory Agents
Therapeutic Uses
Pharmacologic Actions
Antiemetics
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Central Nervous System Agents
Gastrointestinal Agents
Glucocorticoids
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Antineoplastic Agents, Hormonal
Antineoplastic Agents

ClinicalTrials.gov processed this record on September 30, 2014